Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Mar 6, 2026

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
07:43

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

20.0K

Surgery for prolactinoma.

Mendel Castle-Kirszbaum1, Ann McCormack2

  • 1Department of Neurosurgery, Monash Health, Melbourne, Australia; Department of Surgery, Monash University, Australia.

Best Practice & Research. Clinical Endocrinology & Metabolism
|March 4, 2026
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world insights in the use of temozolomide for aggressive pituitary tumours remind us what we still don't know.

Pituitary·2026
Same author

Improving the Assessment of Visual Outcomes After Resection of Tuberculum Sellae Meningiomas.

Neurosurgery·2026
Same author

The fundal cerebrospinal fluid cap in vestibular schwannoma surgery: a predictor of outcome after the retrosigmoid approach.

Neurosurgical review·2026
Same author

Pituitary stalk biopsy - A systematic review of the safety and efficacy of stalk lesion biopsy.

Pituitary·2026
Same author

Lumbar Microdiscectomy and Postoperative Activity Restrictions: A Randomized Controlled Trial.

Spine·2026
Same author

Detection of Optic Canal Invasion in Suprasellar Meningiomas on MRI: Education Improves Clinician Accuracy and Interrater Reliability.

AJNR. American journal of neuroradiology·2026
Same journal

Control of muscle mass and accretion.

Best practice & research. Clinical endocrinology & metabolism·2026
Same journal

Multiple endocrine neoplasia type 2: From molecular genetics to precision therapy.

Best practice & research. Clinical endocrinology & metabolism·2026
Same journal

Nutritional advice for patients with obesity and prediabetes.

Best practice & research. Clinical endocrinology & metabolism·2026
Same journal

Effects of prolonged physical training on skeletal muscle mass accrual throughout the life span.

Best practice & research. Clinical endocrinology & metabolism·2026
Same journal

Type 2 diabetes and obesity in South Asian patients with polyendocrine metabolic ovarian syndrome: The emerging role of metabolomics.

Best practice & research. Clinical endocrinology & metabolism·2026
Same journal

Stress and the interaction of the hypothalamic-pituitary-adrenal axis with other pituitary axes and its consequences on muscle mass.

Best practice & research. Clinical endocrinology & metabolism·2026
See all related articles

Surgery offers higher remission rates for prolactinomas (pituitary neuroendocrine tumours) than dopamine agonists, with fewer side effects. Early referral to specialized centers ensures optimal, individualized treatment decisions for these common pituitary tumors.

Area of Science:

  • Neuroendocrinology
  • Oncology
  • Neurosurgery

Background:

  • Prolactinomas, a type of lactotroph pituitary neuroendocrine tumor, are common and impact quality of life.
  • Dopamine agonists (DA) control prolactinomas but have low remission rates and psychiatric side effects.
  • Surgical outcomes for prolactinomas have improved with advanced techniques.

Purpose of the Study:

  • To compare the efficacy and safety of surgery versus dopamine agonists for prolactinoma treatment.
  • To evaluate the benefits of surgical remission in mitigating long-term treatment burdens.
  • To inform decision-making regarding upfront surgery versus upfront medical management.

Main Methods:

  • Comparative analysis of surgical outcomes versus dopamine agonist therapy.
Keywords:
cabergolinedopamine agonistendoscopicprolactinprolactinomasurgerytranssphenoidal

More Related Videos

Full-Endoscopic Surgery for Hypothalamic Hamartoma Resection
02:22

Full-Endoscopic Surgery for Hypothalamic Hamartoma Resection

Published on: April 12, 2024

1.1K
Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.
06:04

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.

Published on: March 6, 2018

17.7K

Related Experiment Videos

Last Updated: Mar 6, 2026

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
07:43

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

20.0K
Full-Endoscopic Surgery for Hypothalamic Hamartoma Resection
02:22

Full-Endoscopic Surgery for Hypothalamic Hamartoma Resection

Published on: April 12, 2024

1.1K
Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.
06:04

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.

Published on: March 6, 2018

17.7K
  • Review of current evidence on surgical techniques for varying tumor sizes and invasiveness.
  • Discussion of multidisciplinary approaches for patient management.

    • Main Results:

    • Surgery achieves higher biochemical remission rates than DA for microadenomas and non-invasive macroadenomas.
    • Surgical remission avoids DA-related side effects, costs, and treatment anxiety.
    • Even invasive tumors may be candidates for curative resection with surgical advancements.

    Conclusions:

    • Surgery is a safe and effective option for many prolactinomas, offering superior remission rates and fewer long-term complications than DA therapy.
    • Individualized treatment decisions, weighing surgical risks against benefits, are crucial and best made at specialized pituitary tumor centers.
    • Further research is needed to identify optimal candidates for upfront surgery and the impact of preoperative DA therapy.